Payment overview · 2025
General Payments
$152.25
8 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Brockett, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARIETTA, OH · NPI 1366419343
Verified facts
What the public records show
CMS Open Payments records show Michael Brockett, MD received $152.25 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 400 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 400 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.10 | 30.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.07 | 25.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.97 | 13.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.05 | 12.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.49 | 10.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.57 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.25 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.07 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.07 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
400 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
400 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1148 | 157 |
| Atorvastatin Calcium | Atorvastatin Calcium | 967 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 851 | 178 |
| Lisinopril | Lisinopril | 802 | 184 |
| Pantoprazole Sodium | Pantoprazole Sodium | 774 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 592 | 114 |
| Omeprazole | Omeprazole | 568 | 99 |
| Furosemide | Furosemide | 552 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 474 | 106 |
| Metformin Hcl | Metformin Hcl | 426 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 425 | 89 |
| Alprazolam | Alprazolam | 407 | 113 |
| Sertraline Hcl | Sertraline Hcl | 401 | 46 |
| Eliquis | Apixaban | 400 | 47 |
| Potassium Chloride | Potassium Chloride | 400 | 60 |
| Losartan Potassium | Losartan Potassium | 385 | 86 |
| Simvastatin | Simvastatin | 379 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 332 | 84 |
| Buspirone Hcl | Buspirone Hcl | 318 | 41 |
| Allopurinol | Allopurinol | 302 | 41 |
| Gabapentin | Gabapentin | 302 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 271 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 270 | 70 |
| Trazodone Hcl | Trazodone Hcl | 260 | 38 |
| Donepezil Hcl | Donepezil Hcl | 236 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 63 |
| Famotidine | Famotidine | 216 | 35 |
| Tramadol Hcl | Tramadol Hcl | 210 | 63 |
| Valsartan | Valsartan | 210 | 48 |
| Glimepiride | Glimepiride | 186 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 35 |
| Carvedilol | Carvedilol | 165 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 161 | 26 |
| Meloxicam | Meloxicam | 160 | 48 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 155 | 15 |
| Bupropion Xl | Bupropion Hcl | 145 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 27 |
| Lorazepam | Lorazepam | 141 | 33 |
| Montelukast Sodium | Montelukast Sodium | 139 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 127 | 16 |
| Finasteride | Finasteride | 126 | 21 |
| Cephalexin | Cephalexin | 123 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 17 |
| Spironolactone | Spironolactone | 117 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 116 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 114 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 113 | 74 |
| Atenolol | Atenolol | 106 | 32 |
| Azithromycin | Azithromycin | 104 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 37 |
| Sucralfate | Sucralfate | 101 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 18 |
| Mirtazapine | Mirtazapine | 100 | 12 |
| Fenofibrate | Fenofibrate | 97 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 19 |
| Olanzapine | Olanzapine | 89 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 88 | 19 |
| Memantine Hcl | Memantine Hcl | 87 | 12 |
| Jardiance | Empagliflozin | 85 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 75 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 29 |
| Lovastatin | Lovastatin | 72 | 16 |
| Pregabalin | Pregabalin | 72 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 15 |
| Ezetimibe | Ezetimibe | 70 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 69 | suppressed |
| Cefdinir | Cefdinir | 68 | 57 |
| Synthroid | Levothyroxine Sodium | 67 | 19 |
| Diazepam | Diazepam | 65 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | 17 |
| Xarelto | Rivaroxaban | 65 | 11 |
| Methylprednisolone | Methylprednisolone | 64 | 50 |
| Farxiga | Dapagliflozin Propanediol | 63 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 18 |
| Ozempic | Semaglutide | 60 | 13 |
| Meclizine Hcl | Meclizine Hcl | 57 | 23 |
| Metformin Hcl Er | Metformin Hcl | 56 | 18 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 55 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 53 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 48 | 48 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Nifedipine Er | Nifedipine | 44 | 13 |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Temazepam | Temazepam | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 18 |
| Colchicine | Colchicine | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 13 |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Cimetidine | Cimetidine | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Prednisone | Prednisone | 37 | 12 |
| Nystatin | Nystatin | 36 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 17 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 13 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 15 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 17 |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 19 | 19 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Nitroglycerin | Nitroglycerin | 19 | 16 |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dotti | Estradiol | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.25 · 8 records | ABBVIE INC. | AIRSUPRA, AREXVY, BOTOX, CAMZYOS, JARDIANCE, QULIPTA, SHINGRIX, UBRELVY | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error